{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-279016","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.235883+00:00","generated_at":"2026-05-29T02:49:33.841596+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"KalVista appoints Jeb Ledell as COO; base salary $500k, 100k stock options","bullets":["Jebediah T. Ledell appointed COO effective December 16, 2024; brings 20+ years biotech ops experience.","Compensation: $500k base salary, 40% bonus target, inducement options for 100,000 shares vesting over 4 years.","Ledell previously COO at AVEO Oncology, Enzyvant Therapeutics, Compass Therapeutics, and Horizon Discovery Group.","Appointment supports KalVista's preparation for potential sebetralstat launch (HAE); PDUFA goal date June 17, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-279016","json":"https://secwatch.observer/filing/0001193125-24-279016.json","markdown":"https://secwatch.observer/filing/0001193125-24-279016.md","text":"https://secwatch.observer/filing/0001193125-24-279016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000119312524279016/0001193125-24-279016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000119312524279016/d866245d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:49:33.841596+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}